Advertisement

Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement

Jan

18

Today In Oncology

Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides

HCC LLM Advice and Treatment Concordance

Can a Genetic Variant Affect the Efficacy of Abiraterone

Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence

What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?

Advertisement

© 2026 HSP News Service, L.L.C.